OpenOutcrier
Posted - 8 hours ago
$SNY (+4.6% pre) SNY Stock Earnings: Sanofi Beats EPS, Beats Revenue for Q1 2024 https://investorplace.com/earning-results/2024/04/sny-stock-earnings-sanofi-for-q1-of-2024/
DonCorleone77
Posted - 10 hours ago
$SNY Sanofi expects FY24 business EPS to remain relatively stable Sanofi expects 2024 business EPS to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease low single-digit at CER including the higher expected tax rate, barring unforeseen major adverse events. Applying average April 2024 exchange rates, the currency impact on 2024 business EPS is estimated between -5.5% to -6.5%.
DonCorleone77
Posted - 10 hours ago
$SNY Sanofi reports Q1 IRFS EPS EUR 0.91, down 43.1% Reports business EPS of EUR 1.78, down 17.6% reported and 7.4% at CER. Reports Q1 IRFS net sales EUR 10.464B, up 2.4%. Paul Hudson, Chief Executive Officer, commented: "We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Continued strong performance by Dupixent and our new launches drove sales growth of seven percent. In parallel, we are delivering on our promise of increased investments in our late-stage pipeline to fully realize its value for patients and Sanofi. We are awaiting regulatory decisions for Dupixent in COPD, a progressive disease with limited effective treatment options. If approved, Dupixent will be the first biologic treatment in COPD. With the robust progress in our portfolio transformation, we reaffirm our financial guidance for 2024."
zachcole
Posted - 1 day ago
$JNJ good swing through $SNY earnings
Quantumup
Posted - 3 days ago
Oppenheimer🏁 $KYMR OP/$53 KYMR has the pot 2 deliver 1st/best-in-indication, Tx's in inflammation/immunology thru the pursuit of validated🎯s/pathways=multi-billion $ oppys if successful. 📝KT-474(IRAK4) P'ship w/ $SNY + $750M cash which believes will take KYMR into 2027: $arvn $pfe
DonCorleone77
Posted - 3 days ago
$SNY Previously announced Zantac settlement worth $100M, Bloomberg says Sanofi will pay more than $100M to settle about 4,000 lawsuits accusing the company of failing to warn users that its Zantac heartburn medicine could cause cancer, Jef Feeley of Bloomberg reports, citing people familiar with the deal. The settlement was announced earlier this month, but the amount was not made public at that time Feeley notes. The deal provides former Zantac users with an average of more than $25,000 per claim, sources told Bloomberg. Shares of Sanofi are up 1% to $46.90 following the report.
DonCorleone77
Posted - 3 days ago
$SNY Sanofi to pay $100M to settle Zantac cancer lawsuits, Bloomberg says
Sarge986
Posted - 6 days ago
. MIDCAP FOCUS: Is It Showtime for Paramount Global Buyers? $PARA $APO $SNY #MarketRecon . https://pro.thestreet.com/trade-ideas/is-it-showtime-for-paramount-global-buyers
DonCorleone77
Posted - 1 week ago
$IGMS $SNY IGM Biosciences weakness creates 'interesting opportunity,' says Stifel After IGM Biosciences (IGMS) announced that the company's exclusive worldwide collaboration agreement with Sanofi (SNY) to create and develop IgM agonist antibodies will now focus exclusively on immunology and inflammation targets, Stifel analyst Stephen Willey said the firm believes the re-focusing of the collaboration away from oncology and exclusively to the three, yet-to-be-disclosed IAI targets "removes some longer-term economic optionality," but ultimately doesn't change the firm's thesis on the stock. The firm, which adds that Sanofi's decision aligns with its continued prioritization of IAI development opportunities and doesn't reflect anything aplitabart-related and notes that IGM now regains full control of these oncology programs and could potentially re-monetize these assets via future partnerships, would be buyers on related weakness. Stifel has a Buy rating and $25 price target on IGM Biosciences shares.
DonCorleone77
Posted - 1 week ago
$IGMS $SNY IGM Biosciences announces refocusing of Sanofi collaboration IGM Biosciences (IGMS) announced that the Company's exclusive worldwide collaboration agreement with Sanofi (SNY) to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets. IGM will retain global rights to its proprietary technology related to the oncology targets nominated by Sanofi under the collaboration. As previously announced, under the terms of the collaboration agreement, for each of the three Sanofi designated immunology/inflammation targets, IGM will lead research and development activities and assume related costs through the completion of a Phase 1 clinical trial for up to two constructs directed to each target, after which Sanofi will be responsible for all future development and commercialization activities and associated costs. IGM will be eligible to receive up to $1,065 million in aggregate development, regulatory and commercial milestones per target as well as tiered high single-digit to low-teen royalties on global net sales.
RonIsWrong
Posted - 1 week ago
$XBI GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma As published in The New England Journal of Medicine early this month, patients with Parkinson's who took lixisenatide, an injectable marketed by Sanofi ($SNY), witnessed no worsening of their motor disabilities at 12 months. Despite the relatively smaller sample size and a typical GLP-1-like adverse event profile, the effect on the trial's primary endpoint was "sizeable and clinically meaningful," Barclays analyst Carter Gould wrote. $LLY $NVO
Quantumup
Posted - 2 weeks ago
JPM $NRIX OW/$30 W/ generally growing appreciation of the clinical pot of the BTK degrader class/ $NRIX 's pipeline positioning w/in it, JPM anticipates the mid-Y NX-5948 Ph1 update in CLL + contd progress 2ward pipeline exp in I&I =levers4shrs2remain constructive: #AARC $SNY $GILD
Diefreeandsell
Posted - 2 weeks ago
@I_AM_RE_TURDED @albiegf13 ohh, I'm so not surprised. $mrk, $pfe, $AZN $SNY anyone else?
DonCorleone77
Posted - 2 weeks ago
$SNY Sanofi announces launch of Verorab in UK Sanofi has announced the launch of Verorab in the UK, an inactivated rabies vaccine indicated for pre-exposure and post-exposure prophylaxis of rabies in all age groups. This launch is based on extensive clinical data from over 13,000 individuals. Sanofi Inactivated Rabies Vaccine has been approved and widely used in more than 80 countries. It is estimated that between 41M-70M individuals have received the vaccine since its first licensure in May 1985, in France.
Stock_Titan
Posted - 2 weeks ago
$SNY Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups
https://www.stocktitan.net/news/SNY/sanofi-announces-launch-of-verorab-r-sanofi-inactivated-rabies-xe138o4lic2r.html
OpenOutcrier
Posted - 3 weeks ago
$SNY (+0.9% pre) Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts - Reuters https://ooc.bz/l/29441
DonCorleone77
Posted - 3 weeks ago
$SNY Sanofi to resolve roughly 5,000 Zantac lawsuits in U.S., Bloomberg says Sanofi will settle approximately 5,000 lawsuits claiming the French company sold its Zantac heartburn medicine without warning that it could potentially cause cancer, Bloomberg's Jef Feeley, Anna Edney, and Tim Loh report, citing people familiar with the deal. The agreement covers cases around the medicine in five states, including New York, Pennsylvania, and Illinois, the authors note.
NewsByNick
Posted - 3 weeks ago
(Bloomberg) - Sanofi SA has agreed to settle about 5,000 lawsuits accusing the French drugmaker of selling its Zantac heartburn medicine without warning patients that it could cause cancer, according to people familiar with the deal. $SNY https://www.bloomberg.com/news/articles/2024-04-03/sanofi-agrees-to-settle-about-5-000-zantac-cancer-suits-in-us?sref=TBDibEcD
Quantumup
Posted - 03/27/24
RBC Capital⬆️PT $KRRO $90 was $70/Outperform~on⬆️conviction for A1AT — thinks KRRO can tackle a broader mkt (liver/lung) w/ preclin data, including non-human primates (NHP) that has shown pot for BiC; sees pot upside into $WVE clin data later this year. rhhby gsk $lly $inbx $sny
DonCorleone77
Posted - 03/27/24
$RDY $SNY Dr. Reddy's enters partnership with Sanofi to distribute vaccines in India Dr. Reddy's Laboratories (RDY) announced that it has entered into an exclusive partnership with Sanofi Healthcare India (SNY) to promote and distribute Sanofi's vaccine brands across private markets in India. Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's pediatric and adult vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim. Sanofi will continue to own, manufacture, and import these brands to the country.
DonCorleone77
Posted - 03/27/24
$AZN $SNY AstraZeneca, Sanofi announce Beyfortus approved in Japan AstraZeneca (AZN) and Sanofi's (SNY) Beyfortus, a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of lower respiratory tract disease, LRTD, caused by respiratory syncytial virus, RSV, in all neonates, infants and children entering their first RSV season, and the prevention of RSV LRTD in neonates, infants and children at risk of serious RSV infection entering their first or second RSV season. Beyfortus is anticipated to be available for the upcoming 2024/25 RSV season, in line with existing Japanese guidelines. Iskra Reic, Executive Vice President, Vaccines and Immune Therapies, AstraZeneca, said: "The approval of Beyfortus means it is possible for the first time to prevent serious respiratory disease due to RSV for all infants in Japan and reduce the infectious disease burden on healthcare systems. Beyfortus reflects AstraZeneca's commitment to the scientific development..."
jheerdink
Posted - 03/26/24
$MODD Modular Medical a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the addition of Steve Gemmell as Vice President of Engineering.
https://finance.yahoo.com/news/modular-medical-announces-steve-gemmell-120000542.html
"Gemmell has over 20 years of experience in medical device product development and operations and previously held R&D leadership positions with Cytrellis Biosystems, Inc., Onduo, a joint venture between Sanofi SA $SNY and Verily Life Sciences, and $PODD Insulet Corporation. He has significant expertise in automated insulin delivery, and, in his past positions, led collaboration projects with many other companies in the diabetes space, including Dexcom, Abbott, Therasense, Lifescan and $LLY Eli Lilly."
STCG
Posted - 03/26/24
$DRIO Acquires Upright for 31M, Acquires twill for 30M, gets 30M partnership revenue from $SNY, Acquires AI enables PHYsimax for a few Million.Multiple large partnerships with the blues and other health plans .Access to Millions of more lives than it did a year ago. Is already 3 Months into an inflection year and its market cap is 40M? I have a large position here. not buying more before earnings but will buy more if this stock has any significant price drop. DCA. Personally, I feel a 40 M market cap is way too low for the value thats been built with everything above.
nastento
Posted - 1 month ago
$ARQT one of our competitors is $SNY . Seems like some price movement over there may have some influence over here. Anyways, we were spoiled to hit 12 in the first quarter of 2024
jgarn
Posted - 1 month ago
@swingcobra $SNY also spiked at the same time
hiswelshness
Posted - 1 month ago
@Dogcatfish @RockyRambo2023 Not to belabor the obvious, but it has been Big Pharma $$ shorting this stock forever via their Wall St. proxies. A few independent short sellers may have followed the trends created thereby, but it is and always has been the Big Pharma diabetes cartel that are responsible for the unremitting attack on $MNKD since $SNY got a look under the hood at Afrezza.
STCG
Posted - 1 month ago
$DRIO Who has a prediction on why they haven't announced an earnings date yet. Good/Bad/Neutral? I predict they announce the date this Thursday AM for next Thursday AM call. On a positive, I am glad they didn't Pre-announce earnings. :-) Maybe the acquisition reporting takes extra time? Maybe they are expanding the $sny partnership like thy hinted at? Maybe they want some positive Q1 earnings to roll out at the same as expected Q4? Maybe they are giving that 50K Share ask at $1.56 to sell.
Food4Thought
Posted - 1 month ago
Sanofi also had a chance in 2015. The price for BO is much higher for both Sanofi or AstraZeneca. Just like an impatient investor, the price to buy in later in process will be much higher. Just wait until FOMO kicks and all the shorts have to cover. Just get your pop corn ready over next 3-9 months. Sanofi ($SNY) is backing out of a collaboration with Ardelyx ($ARDX) that could have paid out nearly $200 million, returning a handful of candidate treatments for high phosphates in patients with kidney disease. Under the initial deal, signed early last year, Sanofi paid about $1.3 million up front and promised $198 million more in exchange for the rights to some preclinical treatments for hyperphosphatemia, a condition common among patients with end-stage renal disease or chronic kidney disease.
orde
Posted - 1 month ago
$SNY ATTN
